- Consumer Confidence Improves But Still Shaky
- US Home Prices Up 5th Month, 2nd Straight Quarter
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- FDIC Fund Falls into The Red, Bair Urges Lending
- Ron Paul's Plan to Audit Fed a 'Serious Attack': Mishkin
- US Economy Mired in 'Form of Depression': Rosenberg
- Strong Banks, Weak Credit: Treasury Rethinks TARP
- Fairfax Lawsuit Keeps Heat on Chanos, SAC's Cohen
- Blog: Behind The Scenes With Warren Buffett
- Busch: The Debt-Interest Rate Paradox
- The Lloyd's Prayer, Leggo My Eggo, Plate Hate & Your Emails
- Buy These 'Competitively Positioned' Stocks: Portfolio Manager
- Behind The Scenes With Warren Buffett
- 'Why the American Consumer Will Keep on Buying No Matter What'
- On Assignment: Europe & Asia
- The L.A. Extravaganza: A Test for Auto Shows
- 8 Stocks That Could Gain With Rising GDP
- 5 Stocks That Benefit from Health Care Legislation: Analysts
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- US Home Prices Up 5th Month, 2nd Straight Quarter
- FDIC Fund Falls into The Red, Bair Urges Lending
- GM's Agreement to Sell Saab To Swedish Firm Falls Apart
- Weak Dollar Is Golden for Mining Companies
- Revised GDP Reading Puts Growth at 2.8%; Inflation Tame
- Wave of Debt Payments Facing US Government
- Buyers Look For Bargains At Luxury Condo Auction
- CA "More Profitable" After Saving Energy: CEO
- China Eastern to Complete Shanghai Air Buy by End '09
Text Size 
NEW YORK, Oct 30 (Reuters) - Amylin Pharmaceuticals Inc said on Friday that its Byetta drug has won U.S. regulatory approval for use as a stand-alone medication to improve glycemic control in adults with type 2 diabetes. Previously, it only had U.S. Food and Drug Administration approval for use in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control. Byetta has been used by more than one million patients since its 2005 market introduction, Amylin said in the statement. Byetta, an injected drug, has annual sales of about $700 million. It was the first approved drug from the GLP-1 analog class of Type 2 diabetes medicines that work by stimulating release of insulin only when blood sugar levels are high. The drug is co-marked with Eli Lilly and Co. (Reporting by Phil Wahba; Editing by Gary Hill) Keywords: AMYLIN/ (phil.wahba@thomsonreuters.com; +1 646 223 6128; Reuters Messaging: phil.wahba.reuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Print
Email
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- A new McDonald's in Manhattan is the nation's first to sport a sleek, chic interior imported from stores in London and Paris.
- One shopper explains why he gets up at 3am on the day after Thanksgiving to go shopping every year.
- A diet high in fat and sugar might actually be good for your portfolio.
- From the AIG&T to the Merrill Lychee, Jane Wells lists this year's holiday cocktails.
Data is a real-time snapshot *Data is delayed at least 15 minutes